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Seroepidemiologic studiesIntroduction: Immune profile for influenza viruses is highly changeable over time. Serological studies can
assess the prevalence of influenza, estimate the risk of infection, highlight asymptomatic infection rate
and can also provide data on vaccine coverage. The aims of the study were to evaluate pre-existing
cross-protection against influenza A(H3) drift viruses and to assess influenza immunity in the
Portuguese population.
Materials and methods: We developed a cross-sectional study based on a convenience sample of 626 sera
collected during June 2014, covering all age groups, both gender and all administrative health regions of
Portugal. Sera antibody titers for seasonal and new A(H3) drift influenza virus were evaluated by hemag-
glutination inhibition assay (HI). Seroprevalence to each seasonal influenza vaccine strain virus and to the
new A(H3) drift circulating strain was estimated by age group, gender and region and compared with sea-
sonal influenza-like illness (ILI) incidence rates before and after the study period.
Results: Our findings suggest that seroprevalences of influenza A(H3) (39.9%; 95% CI: 36.2–43.8) and A
(H1)pdm09 (29.7%; 95% CI: 26.3–33.4) antibodies were higher than for influenza B, in line with high
ILI incidence rates for A(H3) followed by A(H1)pdm09, during 2013/2014 season. Low pre-existingz, 1649-
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R. Guiomar et al. / Vaccine 35 (2017) 2092–2099 2093cross-protection against new A(H3) drift viruses were observed in A(H3) seropositive individuals (46%).
Both against influenza A(H1)pdm09 and A(H3) seroprotection was highest in younger than 14-years old.
Protective antibodies against influenza B were highest in those older than 65 years old, especially for B/
Yamagata lineage, 33.3% (95% CI: 25.7–41.9). Women showed a high seroprevalence to influenza,
although without statistical significance, when compared to men. A significant decreasing trend in sero-
protection from north to south regions of Portugal mainland was observed.
Conclusions: Our results emphasize that low seroprotection increases the risk of influenza infection in the
following winter season. Seroepidemiological studies can inform policy makers on the need for vaccina-
tion and additional preventive measures.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
The pattern of influenza virus circulation is unpredictable and
varying between each flu season, thus changing the baseline age
specific immunity in the population after each influenza epidemic
period. Serological surveillance provides estimates of population
immunity level against vaccine preventable diseases [1]. Seroepi-
demiology data monitor the gradual accumulation of susceptible
people, changes in age-specific risk of infection and potential risk
of outbreaks [1]. Data from seroepidemiological studies can guide
intervention actions concerning vaccination programmes and
other preventive measures, especially in high-risk groups. Influ-
enza seroprevalence studies are important contributors to estimate
the true incidence and determine the vulnerable populations to
disease. Data on population immunity is even more important in
pandemic scenarios, being essential to assess pre-existing suscep-
tibility, true infection attack rates, exposure to circulating viruses,
estimate asymptomatic infection rates and inform on vaccine cov-
erage [2,3]. Moreover, seroprevalence surveys are the most practi-
cal method for accurately estimating the infection attack rate (IAR)
in an epidemic such as influenza [4]. However, seroepidemiology
data adds important and valuable information to influenza surveil-
lance and could support decision-making in target groups for vac-
cination, as only a few National Influenza Surveillance Programmes
at European level integrate routinely the serological studies in
National Influenza Surveillance Systems [5–8]. In Portugal, this is
the first seroepidemiological study in the scope of influenza
surveillance that aims at assessing the cross-protection to the
new drift influenza A(H3) viruses determining the prevalence of
seasonal influenza protective antibodies by age, gender and health
region as well as considering the relationship with influenza- like
illness (ILI) incidence rates observed on seasons before and after
the sample collection.2. Materials and methods
To study influenza immunity in the Portuguese population, a
non-probabilistic sample was used. Samples were collected from
people attending to hospital laboratories for other reasons aside
from influenza infection. We developed a cross-sectional study
based on a convenience sample of 626 sera collected during June
2014. Sera were selected from all age groups (0–4; 5–14; 15–64
and 65 years old) and both genders, in equal proportion, at 11
hospital laboratories from the Portuguese Laboratory Network for
the Diagnosis of Influenza Infection [9], covering all administrative
health regions (HR) of Portugal: Norte, Centro, Lisboa e Vale do
Tejo, Alentejo, Algarve and including also the Açores (São Miguel
and Terceira islands) and Madeira islands. For each HR, an equal
representation of all age groups was guaranteed, with the excep-
tion of Algarve that didn’t select samples from individuals under
5. A remaining volume (minimum selected volume 250 ll) ofrecently collected sera that comes to laboratory for serological
analysis, excluding influenza, were selected for the present study.
Sera were randomly selected taking only into account the patient
age. Data regarding vaccination or influenza previous infection
weren‘t recorded, because this information weren‘t available at
patient hospital admission registries. All samples were anon-
ymized and data regarding district of residence or sample collec-
tion, gender and age were recorded.
The present investigation follows the international ethical
guidelines, and was approved by the Health Ethics Committees of
the National Institute of Health Dr. Ricardo Jorge (ref. 17/3/2014)
and by the Hospital of Divino Espírito Santo of Ponta Delgada
(ref. 582/2014).
In all sera, the antibody titers to the influenza virus strains rec-
ommended for the tri and quadrivalent vaccines (northern hemi-
sphere, 2014/2015) were assessed: A/California/7/2009
(AH1pdm09), A/Texas/50/2012 (AH3), B/Massachusstes/02/2012
(B/Yamagata lineage), and B/Brisbane/60/2008 (B/Victoria lineage)
[10]. Sera from all age groups, with protective antibody titers
against A/Texas/50/2012 equal or higher than 80, were tested for
the presence of cross reactive antibodies to the new A(H3) drift
viruses, antigenically different from vaccine strain: A/Switzer-
land/9715293/2013 (3C.3a subclade) and A/Hong Kong/5738/2014
(3C.2a subclade) [11]. The selected 150 sera were distributed
across all age groups and regions, conforming to the distribution
of all A(H3) seropositive samples.
Serum antibody titers were evaluated in duplicate by the tech-
nique of hemagglutination inhibition (HI) according to the stan-
dard methodology [12] in laboratory biosafety level 2 conditions.
Sera were pre-treated with receptor destroying enzyme [RDE (II)
‘‘SEIKEN”; Denka Seiken Co. Ltd.] and tested in two fold serial dilu-
tions starting at 1:10 to a final dilution of 1:1280, using guinea pig
red blood cells. HI endpoint titer was assessed as the reciprocal of
the highest dilution of serum that completely inhibits hemaggluti-
nation. HI titer 40 were considered protective against tested virus
strain [13] and in titers <10, 5 were assigned to enable geometric
means titer (GMT) calculation. The WHO Collaborating Centre in
London kindly provided the influenza reference virus strains and
antiserums. Viruses were grown in Mardin Darbin canine kidney
(MDCK) cells and in Mardin Darbin Canine Kidney Sialic Acid
Over-Expression cells (MDCK-Siat1) [12]. Reference antiserum
and homologous virus strains were tested in each assay.
Seroprevalence estimates are presented with respective 95%
confidence intervals (95% CI). Differences between groups (gender,
age and region) regarding the proportion of sera with antibody
titer considered protective (titer 40) were tested using the chi-
square test, while differences in titers between groups were evalu-
ated using the Kruskal-Wallis test. The level of significance was set
at 5%. All statistical analysis was performed in R version 3.0.3.
Seasonal ILI incidence rates were estimated for each age group
for 2013/2014 and 2014/2015 influenza seasons using data
provided by the Portuguese General Practitioners (GP) sentinel
2094 R. Guiomar et al. / Vaccine 35 (2017) 2092–2099network (Rede Médicos-Sentinela) that reports the number of ILI
cases in a weekly basis since 1990, and is the national ILI incidence
rate indicator. As numerator were considered all ILI cases that have
met ECDC ILI definition [14] with symptoms onset date falling
between week 40/2013 and week 20/2014 or between week
40/2014 and week 20/2015. As denominator was considered the
average of population under observation within the GPs sentinel
network in the same periods. Given that Portuguese GP sentinel
network only collects information on the sample of volunteer
GPs and on ILI cases that required medical attendance, it underes-
timates the true ILI incidence rate and affects the accuracy of
estimates.
Seasonal ILI incidence rate by age group were calculated multi-
plying the proportion of ILI cases positive for each influenza sub-
type and lineage by seasonal ILI incidence rate to obtain a proxy
of seasonal influenza incidence rate by subtype and lineage.
3. Results
For the 626 tested samples (from all age groups) highest preva-
lence of protective antibody titers was detected for A/Tex-
as/50/2012 (39.9%; 95% CI: 36.2–43.8) followed by A/
California/7/2009 (29.7%; 95% CI: 26.3–33.4), B/Mas-
sachusetts/2/2012 (23.0%; 95% CI: 19.9–26.5) and B/Bris-
bane/60/2008 (9.1%; 95% CI: 7.1–11.86).
Seroprevalence rates were also reflected by the geometric
means titers pattern (Table 1).
3.1. Influenza A(H3) seroprevalence
Seroprevalence of protective antibodies against A/Tex-
as/50/2012 was 60.5% (95% CI: 51.7–68.6) in the age group 5–
14 years old, 1.5 times higher than in the general population. It
was followed by the elderly (65 years old) and infants (0–4 years
old) with a seroprevalence of 41.3% (95% CI: 33.1–50.0) and 39.3%
(95% CI: 30.9–48.4), respectively (Fig. 1). We observed the lowest
seroprevalence in adults between 15–64 years old (29.7%; 95%
CI: 24.5–35.6). In both influenza seasons the highest A(H3) inci-
dence rates were observed in children between 5–14, 302.1 ILI
cases/105 inhabitants during 2013/2014 and 577.9 ILI cases/105
inhabitants during 2014/2015 (Fig. 1). Individuals over 64 experi-
enced the lowest A(H3) ILI incidence rates in both seasons (101.3
ILI cases/105 inhabitants in 2013/2014 and 195.6 ILI cases/105
inhabitants in 2014/2015).
3.2. New drift influenza A(H3): A/Hong Kong/5738/2014 and
A/Switzerland/9715293/2013
For all samples with a titer 80 to A/Texas/50/2012 (n = 150),
pre-existing cross protection antibodies titers to A(H3) new drift
variants were assessed: A/Hong Kong/5738/2014 (3C.2a subclade)Table 1
Seroprotection rates against seasonal influenza by hemagglutination inhibition assay (HI t
Viruses Estimation of p HI  40
Number/total
AH1pdm09a 186/626
AH3b 250/626
B_Massc 144/626
B_Brisbd 57/626
p-value* <0.001
* p-value refers to the comparison of ratio of viruses (chi-square test), as well as to th
a A/California/7/2009.
b A/Texas/50/2012.
c B/Massachusetts/2/2012 (Yamagata lineage).
d B/Brisbane/60/2008 (Victoria lineage).and A/Switzerland/9715293/2013 (3C.3a subclade), considered
antigenically different from vaccine strains and previous A(H3) cir-
culating strains. Protective antibodies titers against A/Hong
Kong/5738/2014 and A/Switzerland/9715293/2013 were detected
in 46.0% (95% CI: 38.2–54.0) and 46.7% (95% CI: 38.9–54.6) of the
sera, respectively. Seroprevalence rates were also reflected by geo-
metric means titers pattern (Fig. 2).
Higher percentages of seropositivity to A(H3) new drift viruses
were seen in age groups under 15 and above 64, compatible with
seropositivity to the A(H3) vaccine strain, A/Texas/50/2012
(Table 2). It was also evident by GMT values that in different mag-
nitude the younger (<15) and older ones (>64) were the ones that
shown higher antibody titers to the 3 tested A(H3) virus antigens.
A higher seroprevalence against A/Hong Kong/5738/2014 was
noticed in younger than aged 14; however, to A/Switzer-
land/9715293/2013 strain the higher seroprevalence was observed
in younger than 4 and in adults above 64 years old. Adults between
ages 15 and 64 years old showed the lowest rate of protective anti-
bodies to new circulating A(H3) drift strains, 20.0% (95% CI: 10.9–
33.8) to A/Hong Kong/5738/2014 and 22.2% (95% CI: 12.5–36.3) to
A/Switzerland/9715293/2013 (Table 2).
3.3. Influenza A(H1)pdm09 seroprevalence
Our study showed the highest prevalence of protective antibod-
ies against influenza A(H1)pdm09 (A/California/7/2009) in the age
group of 5–14 years old, corresponding to 44.4% (95% CI: 35.9–
53.1), 1.5 times higher than in general population (Fig. 1). Lowest
seroprevalence against A(H1)pdm09 was found in the elderly
(21.4%; 95% CI: 15.2–29.4). During 2013/2014 season A(H1)
pdm09 co circulated with influenza A(H3) and B, a high incidence
rate for A(H1)pdm09 was observed in children between ages 0 and
4. During 2014/2015 season, the incidence rate for A(H1)pdm09
was very low in all age groups, indicating only a sporadic circula-
tion of this virus subtype [15,16].
3.4. Influenza B seroprevalence
For influenza B, an increase of protective antibodies according
to age was observed. In general, higher antibodies titers to B/Mas-
sachusetts/2/2012 were found when compared to B/Bris-
bane/60/2008. Higher seroprevalence to influenza B strains in
elderly 65 years old was observed [33.3% (95% CI: 25.7–41.9) to
B/Massachusetts/2/2012; 14.3% (95% CI: 9.2–21.5) for B/Bris-
bane/60/2008]. Lowest level of seroprotection was found to influ-
enza B/Brisbane/60/2008 in all age groups, especially in youngest
ones (<4 years old). The seasonal influenza B incidence rate in
2013/2014 was low although during 2014/2015 season influenza
B from Yamagata lineage was the predominant circulating viruses.
High ILI incidence rates in all age groups were observed, being
higher in children between ages 5–14 (770.5 ILI cases/105 inhabi-iter 40) and geometric means titer (GMT) in June 2014 on Portuguese population.
GMT
% 95% CI Value 95% CI
29.7 26.3–33.4 16.4 15.0–18.0
39.9 36.2–43.8 22.6 20.3–25.3
23.0 19.9–26.5 13.6 12.6–14.7
9.1 7.1–11.6 9.6 9.1–10.2
<0.001
e comparison of virus titers (Kruskal-Wallis test).
Fig. 1. Prevalence of protective antibodies (titer 40) by age group against influenza A/California/7/2009 (AH1pdm09), A/Texas/50/2012 (AH3), influenza B B/Massachusetts/
2/2012 (B_Mass) and B/Brisbane/60/2008 (B_Brisb). Seasonal ILI incidence rate by age group during 2013/2014 and 2014/2015 seasons (GP sentinel Network).
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influenza B Yamagata was found in individuals over 65 years old
(316.6 cases/105 inhabitants) (Fig. 1).
3.5. Seroprevalence to 2014/2015 vaccine strains
From all tested samples, only 5.8% (95% IC: 4.1–7.9) had HI
titers 40 for all the 3 influenza vaccine viruses recommended
for 2014/2015 trivalent influenza vaccine [18], indicating a low
proportion of individuals with broad protection for seasonal influ-
enza types and subtypes.
3.6. Seroprevalence by gender
Analysis by gender showed that seroprevalence rates and GMT
to all tested virus strains, including the new drift A(H3), were
higher in the females; however, without statistical significance,
when compared to seroprevalence and GMT in males (Fig. 3).3.7. Geographical pattern of influenza seroprotection
Analysis of seroprotective antibodies in each administrative
health region (HR) of Portugal, including the Açores and Madeira
islands showed a significant difference between regions. A
decreasing trend in seroprotection for influenza, from north to
south of Portugal mainland was observed (Fig. 4). The highest
seroprevalence rate was observed in the north region to A(H3),
69.4% (95% CI: 59.7–77.6) and the lowest seroprevalence rate,
2.6% (95% CI: 0.5–13.5) in Algarve to influenza B/Victoria lineage.
Although Algarve region lack sera from less than 5 years old, this
pattern remains the same when children under 5 from all regions
are excluded from the analysis. Açores and Madeira regions
showed similar seroprotection rates to influenza, although Açores
showed higher seroprotection rates for A(H1)pdm09 and influ-
enza B/Yamagata lineage, 41.0% (95% CI: 31.9–50.8) and 35.0%
(95% CI: 26.4–44.7), respectively. In Madeira, higher seroprotec-
tion rates were observed to A(H3) and B/Victoria, 50.0% (95%
Fig. 2. Seroprotection against A/Hong Kong/5738/2014 (A/Hkong) and A/Switzerland/9715293/2013 (A/Swit) in sera with HI titer 80 to A/Texas/50/2012 (n = 150).
Geometric mean titers for A/Hkong, A/Swit and A/Texas/50/2012 (A/Texas). Errors bars represent 95% confidence interval.
Table 2
Seroprotection against A/Hong Kong/5738/2014 (A/Hkong), A/Switzerland/9715293/2013 (A/Swit), and A/Texas/50/2012 (A/H3) in sera with HI titer 80 to A/Texas/50/2012, by
age group.
Virus Age group HI  40 GMT
Number/total % 95% CI Value 95% CI
A/Hkong 0–4 20/31 64.5 46.9–78.9 31.3 22.5–43.6
5–14 29/48 60.4 46.3–73.0 38.3 29.9–49.0
15–64 9/45 20.0 10.9–33.8 15.9 12.1–20.8
65+ 11/26 42.3 25.5–61.1 27.5 16.7–45.5
A/Swit 0–4 22/31 71.0 53.4–83.9 40.0 29.8–53.6
5–14 23/48 47.9 34.5–61.7 25.6 20.4–32.0
15–64 10/45 22.2 12.5–36.3 14.2 10.7–19.0
65+ 15/26 57.7 38.9–74.5 31.5 20.7–47.8
A/Texas 0–4 31/31 100 – 244.69 190.3–314.6
5–14 48/48 100 – 163.98 134.1–200.4
15–64 45/45 100 – 123.14 101.9–148.9
65+ 26/26 100 – 203.39 145.5–284.3
Fig. 3. Seroprotection rate against influenza vaccine strains by gender. Sera collected in June 2014 were tested by haemagglutination inhibition assay (HI titer 40, protective
titer) and geometric means titer (GMT) (n = 626). Vaccine strains: A/California/7/2009 (AH1pdm09), A/Texas/50/2012 (AH3), B/Massachusetts/2/2012 (B_Mass) and B/
Brisbane/60/2008 (B_Brisb). Errors bars represent 95% confidence interval.
2096 R. Guiomar et al. / Vaccine 35 (2017) 2092–2099CI: 36.4–63.6) and 16.7% (95% CI: 8.7–29.6), compared to Açores.
The differences in seroprevalences to influenza in Açores and
Madeira were not statistically significant. Seroprevalenceswere in accordance with GMT values for each virus and region
(Fig. 4).
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The present study was the first pilot investigation to assess
cross-protection and seroprevalence antibodies to influenza in a
tentative representative sample of the Portuguese population at
the end of 2013/2014 influenza season, in June 2014, interepidemic
period. The study showed cross reactive antibodies to new drifted
A(H3) viruses and protective antibodies rates to each vaccine influ-
enza virus (sub)type for all age groups, gender and health admin-
istrative regions of Portugal.
The seroprotection to each influenza virus type and subtype
ranged from 9 to 40% in the studied population. The observed sero-
protection was significantly different in each age group. The esti-
mated seroprotection rates against influenza A(H3) and A(H1)
pdm09 subtypes were significantly higher compared to influenza
B. This observation is in line with predominant circulating viruses
in 2013/2014 influenza season, A(H1)pdm09 and A(H3) co circu-
lated during all winter while influenza B/Yamagata was detected
sporadically, and represented only 0.7% of detected influenza
viruses [15]. Seroprotection rate against influenza A(H3) virus
was higher in children between 5 and 14 years old. This fact is in
line with the highest seasonal incidence rate observed in this age
group to A(H3) in 2013/2014 season, prior to the study period.
Despite this, during 2014/2015, high A(H3) influenza incidence
rate was observed in all age groups, especially in children aged
5–14 (577.9 ILI cases/105 inhabitants). In fact, 68% (38/56) of anal-
ysed A(H3) circulating strains showed antigenic and genetic char-
acteristics dissimilar from the vaccine and earlier circulating
strains [16] and were identified as new A(H3) drift variants [17].
Those facts suggest a reduced acquired protection to the new drift
A(H3) viruses. In our study, were identified pre-existing cross-
reactive antibodies to the new drifted A(H3) viruses in only half
of the individuals that showed seroprotection to non-drifted
2014/2015 A(H3) vaccine virus. This finding could explain,
together with a limited vaccine effectiveness for A(H3) circulating
viruses [10,18], a reduced seroprotection and an elevated ILI inci-
dence rate observed during 2014/2015 influenza season. Seropro-
tection against new drifted A(H3) viruses was higher in children
followed by individuals aged over 64. Adults between 15 and 64,Fig. 4. Seroprotection rate against influenza by haemagglutination inhibition assay (HI t
collected in June 2014, Portugal (n = 626). Vaccine strains: A/California/7/2009 (AH1pdm
2008 (B_Brisb). Errors bars represent 95% confidence interval.with lower antibody titers to the new drift A(H3), are more suscep-
tible to infection by these viruses. Also adults showed lower sero-
prevalence to influenza A, when compared to other age groups,
being more likely to be susceptible to influenza A(H1)pdm09 and
A(H3) infection [15].
Seroprotection to influenza B is higher in individuals over
15 years old, especially in the elderly (65 years old), as observed
in previous studies [8]. However, seroprevalence to influenza B
from Victoria lineage was observed at low levels of protection
even in older ones. This fact is related to only sporadic circulation
of influenza B Victoria since 2010/2011 winter season [19] and
waning immunity that was described in previous studies as less
persistent than for influenza A [20]. Influenza B Victoria was
detected in circulation in 2010/2011 and since then only influ-
enza B Yamagata was detected during 2012/2013 and
2014/2015. Low number and sporadic cases of influenza B infec-
tions were identified during 2011/2012 and 2013/2014 when
influenza A predominated. The prevalence of antibodies against
influenza B increases with age, for both Yamagata and Victoria
lineage, suggesting long-lasting memory immunity for this virus
type [21]. Children under 4, born after 2010, were the most vul-
nerable individuals to influenza B infection showing lower sero-
prevalence rates. Most of these children had only been exposed
once to influenza B Yamagata, before sample collection (July
2014), as this virus only circulated in high level during
2012/2013 winter season, in line with the lowest seroprevalence
detected in younger ones in the present study. Previous studies
described that detectable antibodies to influenza in children
gradually increase with age, approximately 60–70% of all children
up to the age of 12 were serologically naïve and have to be con-
sidered susceptible to influenza B, such being detected in more
than 90% of children only at age of 18 years [8].
The low proportion of samples with protective antibodies
against the three vaccine strains (5.8%) is in line with the low vac-
cine coverage estimates for 2013/14 season in the general popula-
tion and elderly (17.1% and 49.9%, respectively) [22]. But given that
our study was set up during an interepidemic period, it could also
be linked to the waning of vaccine protection observed a few
months after vaccination [23].iter 40) and geometric means titer (GMT) by administrative health region, in sera
09), A/Texas/50/2012 (AH3), B/Massachusetts/2/2012 (B_Mass) and B/Brisbane/60/
2098 R. Guiomar et al. / Vaccine 35 (2017) 2092–2099However, without statistical significance, women showed
higher seroprevalence to influenza, as shown by a previous study
[8]. This immune response might be linked to hormones and
genetic sex-based differences that interfere with antibody produc-
tion by both genders [24]. It should also be considered that women
are the ones that usually take care of the children which allows a
more direct contact and could favours the transmission of influ-
enza virus by the children, one of the groups with high influenza
incidence.
Across Portugal, higher seroprotection rates were identified in
the north health administrative region with a decreasing trend to
the south of Portugal mainland. In the scope of the National Influ-
enza Surveillance Program the north region accounted for the high-
est percentage of influenza A detected viruses, during 2013/2014
season, in correlations with serological findings [15].
We acknowledge some limitations in our serological study.
Information regarding neither influenza vaccination nor influenza
previous infection during 2013/2014 season were collected for
each patient, limiting the interpretation of sources for acquired
immunity to influenza, thus making it impossible to differentiate
between seropositivity due to natural infection or immunization.
Titer of 1:40 that correlates with a 50% reduction of the risk of
infection was assumed for all age groups although previous studies
suggest a higher HI cut off titer for children [25,26]. It should also
be mentioned that detected antibodies by HI does not fully corre-
spond to all functional antibodies [26], and cellular immunity was
not evaluated, although it is also related to protection [5,13].
There are some limitations recognized about the sampling
because a non-probabilistic sample was used, however samples
were collected during a period without influenza circulation in
the community, June 2014 [27] and selected in hospitals from
the Portuguese Laboratory Network, covering all administrative
health regions, Portugal mainland and the Açores and Madeira
Islands. Cross-protection against the new drift A(H3) influenza
virus was evaluated in a sample of sera positive for non-drifted
virus, with HI titer 80, adding some imprecision to the calculated
seroprevelence for A(H3) new drift strains. Nevertheless, this sam-
ple was distributed across all study population and covered all age
groups with a distribution similar to the overall A(H3) positive
samples. To determine seroprotection to influenza B was not per-
formed ether-treatment of the influenza B antigens for HI assay,
prioritizing increased specificity at the expense of sensitivity
[28–31]. Study seroprevalence results showed consistency with
the viruses that circulated before and after the study, although it
should be assumed caution has prevalence of influenza B seropro-
tection could be underestimated. The sample size and previous
data on ILI incidence rates by age group only enabled the analysis
of four age group categories, resulting in a broad age group, espe-
cially in adults aged 15–64 disallowing evidence patterns within
subgroups of this population. In future serosurvey studies and in
influenza surveillance program will be collected the date of birth
for each ILI case and will be increased the number of sera selected
for serological evaluation to enable desegregation of considered
age groups. A single-year observation imposes some limitation
on data interpretation. To have antibody prevalence data before
and after the influenza annual epidemic the authors plan to repeat
this serosurvey annually to track the effects of the outbreaks in the
population seroprevalence and immunity.5. Conclusions
The main strength of our findings is the close relation of sero-
prevalence and the dominant influenza virus in previous and fol-
lowing influenza season. Overall, our results suggested that at
the end of 2013/2014 season, the Portuguese population was moresusceptible to influenza B, in particular the younger ones, consis-
tent with a predominant circulation of influenza B in the winter
following the study, 2014/2015 influenza season. However, this
should be interpreted with caution due to a possible underesti-
mated seroprevalence to influenza B. The higher ILI incidence rates
in 5–14 age group, highlights the potential of this group to spread
influenza in the community. Also evident for influenza B is the
importance of a memory immunity in older individuals. Limited
pre-existing cross reactive antibodies to the new drift A(H3) strains
in the general population were observed. Only half of seropositives
to influenza A(H3) vaccine strain showed seroprotection to the
new drift A(H3) strains. This is in correlation with the high A(H3)
incidence rates during 2014/2015 season, in spite of the high A
(H3) seroprevalence observed in 2014. A low proportion of all pop-
ulation had broad protection to all seasonal influenza viruses, thus
suggesting low vaccine uptake, and the need for intervention and
recommendations on preventive measures.
In the future, serology studies should be taken in the scope of
influenza surveillance programmes to better understand the
dynamic of influenza transmission, seroprotection in population
and establish an annual immunological profile to identify most
vulnerable age groups for influenza infection in each winter
season.
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